Date: 2016-02-23
Type of information: Opening of new premises
Compound: clinical trials unit
Company: Juno Therapeutics (USA - WA) Fred Hutchinson Cancer Research Center (USA - WA)
Therapeutic area: Cancer - Oncology
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On February 23, 2016, Juno Therapeutics and Fred Hutchinson Cancer Research Center announced the creation of a new, best-in-class clinical trials unit (CTU) dedicated to immuno-oncology. University of Washington, the Seattle Cancer Care Alliance (SCCA), Fred Hutch, and Juno are all investing in the CTU, and Juno will also provide research funds to Fred Hutch in support of pre-clinical and clinical research focused on the development of improved cancer immunotherapies.
The CTU will enable patients participating in clinical trials to get all of their care at a single site, with a team of dedicated surgeons, radiologists, pathologists and medical oncologists. In addition to consolidating trial participants’ care into one location, the new unit will have dedicated space for research teams to handle specimens and collect trial data. The CTU is expected to be operational in mid-2016 and will be available for studies supported by Juno and other drugmaker
Financial terms:
Latest news:
